In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Nguyen D Tran *Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Nhu T Q Nguyen *Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-2203-950X Trang T T VuDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Phung-Hieu DiepDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0009-0006-2149-5702 Naomi N VillescasDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Nhi N Y NguyenDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Kei M SatoDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
William J WeissPre-Clinical Services at UNT Health Science Center, Fort Worth, Texas, USA.
Thien N M DoanDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0009-0000-9364-7580 Binh An DiepDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-9070-1542 Funding
FDA HHS HHSF223201710112C
6 · The paper itselfAbstract
Translating preclinical findings into clinical success remains a major barrier in the development of antimicrobials targeting
Indexed as
Anti-Bacterial AgentsCiprofloxacinPseudomonas aeruginosaPseudomonas InfectionsShock, SepticAnimalsDisease Models, AnimalDrug DevelopmentFemaleMaleMicrobial Sensitivity TestsRabbitsAnti-Bacterial AgentsCiprofloxacinfluid resuscitationhyperdynamic statemechanical ventilationpreclinical efficacy model validationPseudomonas aeruginosarabbit modelseptic shockvasopressor
Identifiers
PMID42295241
PMCPMC13435728
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390